Fluorodeoxyglucose positron emission tomography in semantic dementia after 6 months of memantine: an open‐label pilot study

To follow up on the increases we reported in normalized metabolic activity in salience network hubs from a 2‐month open‐label study of memantine in frontotemporal dementia (FTD).

[1]  Alan A. Wilson,et al.  Open-label study of the short-term effects of memantine on FDG-PET in frontotemporal dementia , 2011, Neuropsychiatric disease and treatment.

[2]  C. Volteau,et al.  Memantine in behavioral variant frontotemporal dementia: negative results. , 2011, Journal of Alzheimer's disease : JAD.

[3]  M. Mandelkern,et al.  Effect of memantine treatment on regional cortical metabolism in Alzheimer's disease. , 2010, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[4]  Efstathios D. Gennatas,et al.  Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. , 2010, Brain : a journal of neurology.

[5]  M. Freedman,et al.  Frontotemporal dementia and pharmacologic interventions. , 2010, The Journal of neuropsychiatry and clinical neurosciences.

[6]  Bruce G. Pollock,et al.  Test-retest variability of high resolution positron emission tomography (PET) imaging of cortical serotonin (5HT2A) receptors in older, healthy adults , 2009, BMC Medical Imaging.

[7]  David Eidelberg,et al.  Cholinergic modulation of the cerebral metabolic response to citalopram in Alzheimer's disease. , 2009, Brain : a journal of neurology.

[8]  Nathaniel Mercaldo,et al.  Development of methodology for conducting clinical trials in frontotemporal lobar degeneration. , 2008, Brain : a journal of neurology.

[9]  Hans Förstl,et al.  A 6‐month, open‐label study of memantine in patients with frontotemporal dementia , 2008, International journal of geriatric psychiatry.

[10]  Jean-Claude Baron,et al.  Decomposition of metabolic brain clusters in the frontal variant of frontotemporal dementia , 2006, NeuroImage.

[11]  Karl Herholz,et al.  Predominant ventromedial frontopolar metabolic impairment in frontotemporal dementia , 2003, NeuroImage.

[12]  J. Kornhuber,et al.  Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.

[13]  The Unified Parkinson's Disease Rating Scale (UPDRS): Status and recommendations , 2003, Movement disorders : official journal of the Movement Disorder Society.

[14]  M. Ikeda,et al.  The Stereotypy Rating Inventory for frontotemporal lobar degeneration , 2002, Psychiatry Research.

[15]  S. Potkin,et al.  Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. , 2001, The international journal of neuropsychopharmacology.

[16]  D. Royall,et al.  The FAB: A frontal assessment battery at bedside , 2001, Neurology.

[17]  I Litvan,et al.  The FAB: A frontal assessment battery at bedside , 2000, Neurology.

[18]  R. Faber,et al.  Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. , 1999, Neurology.

[19]  M. Freedman,et al.  Frontotemporal lobar degeneration , 1998, Neurology.

[20]  A. Kertesz,et al.  Frontal Behavioral Inventory: Diagnostic Criteria for Frontal Lobe Dementi , 1997, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[21]  R. Robinson,et al.  Specificity of changes in cerebral blood flow in patients with frontal lobe dementia. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[22]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.